Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). [electronic resource]
Producer: 20030904Description: 120-9 p. digitalISSN:- 0041-1337
- Adult
- Alemtuzumab
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- therapeutic use
- Black People
- Female
- Follow-Up Studies
- Graft Rejection -- epidemiology
- Graft Survival -- drug effects
- Humans
- Immunosuppressive Agents -- therapeutic use
- Kidney Transplantation -- immunology
- Lymph Nodes -- immunology
- Lymphocyte Depletion
- Male
- Middle Aged
- T-Lymphocytes -- immunology
- Time Factors
- Transplantation, Homologous
- United States
- White People
- Black or African American
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.